Join the managers of SAINTS on their travels as they seek out companies from across the globe that they believe can deliver the winning combination of dependable and growing income along with capital growth. Capital is at risk and income is not guaranteed. A key information document is available by contacting Baillie Gifford.
The negative mood enveloping UK equities looks overdone – we argue there are compelling reasons to invest at the current time.
Major headwinds caused by various factors weighed on investor sentiment in the healthcare sector during the second quarter. BB Biotech was not completely immune to these developments and delivered a return of 1.2% in EUR.
A handful of giant tech companies have led the global bull market, thanks to their rapid earnings growth. While privacy and political issues bear watching, we believe the growth potential of these firms outweighs regulatory risks. The tech giants have been the driver of an extended cycle of outperformance for growth investors. Whether growth continues…
Nicolas Trindade, manager of the AXA Global Short Duration Bond Fund, expects the rise in volatility witnessed at the start of 2018 to continue into the second half of the year and as a result is adopting a cautious stance within the portfolio. Describing 2018 so far as a “challenging year”, Trindade said a combination…
The rise of populism is increasing the risk of a near-term policy shock, and thus of renewed market volatility. While we believe the fundamental environment remains sound, risks are rising. This suggests that prudent investors may want to consider positioning portfolios more conservatively, at least at the margin.
Big players in the healthcare sector are desperate to differentiate their approved ‘checkpoint inhibitors’ (a drug that unleashes an immune system attack on cancer cells) by combining their use with conventional chemotherapy or other new drugs. Biotechnology firms are developing many of these next-generation combination agents as well as continuing to strengthen their positions in…
At first glance, Japan appears to be in a sweet spot. A combination of structural reforms, a stable political environment and consistently easy monetary policy has revitalized the country’s economy since 2012.
Despite market volatility in Q1, BB Biotech performed very well with an overall return of 8.8% in CHF. Several large biotech companies are currently trading below their fundamental value,and offer an attractive entry level for investors.
Biotech companies are increasingly pioneering groundbreaking therapies for diseases with high-unmet medical need. Investing in these innovation leaders is a hallmark of BB Biotech’s investment philosophy.
Many companies are mispriced because they are misunderstood. Find out how a disciplined valuation approach is uncovering opportunity in overlooked areas of corporate Japan. This year has been characterized by very large swings in market sentiment for Japan equities. Increasing market volatility has coincided with short-term news linked to both comfort with and concern for…
2017 was a better year for active equity managers, but over the long run the results look less healthy. Skill isn’t spread evenly – some managers are much better than others. With returns harder to come by in a world nearing normal, and regulatory changes putting fees under the microscope, knowing where to put your…
